Synthesis and biological evaluation of novel tamoxifen analogues. 2013

Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
Chemistry Laboratory, Agricultural University of Athens, Iera Odos 75, Athens 11855, Greece.

A collection of compounds, structurally related to the anticancer drug tamoxifen, used in breast cancer therapy, were designed and synthesized as potential anticancer agents. McMurry coupling reaction was used as the key synthetic step in the preparation of these analogues and the structural assignment of E, Z isomers was determined on the basis of 2D-NOESY experiments. The compounds were evaluated for their antiproliferative activity on breast cancer (MCF-7), cervix adenocarcinoma (HeLa) and biphasic mesothelioma (MSTO-211H) human tumor cell lines. The estrogen like properties of the novel compounds were compared with those of the untreated controls using an estrogen responsive element-based (ERE) luciferase reporter assay and compared to 17β-estradiol (E2). Finally, with the aim to correlate the antiproliferative activity with an intracellular target(s), the effect on relaxation activity of DNA topoisomerases I and II was assayed.

UI MeSH Term Description Entries
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
September 2013, Bioorganic & medicinal chemistry letters,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
August 2018, European journal of medicinal chemistry,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
October 2017, Organic & biomolecular chemistry,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
August 2006, Bioorganic & medicinal chemistry,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
July 2021, Bioorganic & medicinal chemistry,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
May 2019, Organic & biomolecular chemistry,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
May 2007, Bioorganic & medicinal chemistry letters,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
January 2017, Frontiers in chemistry,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
August 2016, Molecular diversity,
Michael S Christodoulou, and Nikolas Fokialakis, and Daniele Passarella, and Aída Nelly García-Argáez, and Ornella Maria Gia, and Ingemar Pongratz, and Lisa Dalla Via, and Serkos A Haroutounian
August 2001, Organic letters,
Copied contents to your clipboard!